Text Size

A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Noxxon Pharma AG
ClinicalTrials.gov Identifier:
NCT01372124
First received: June 8, 2011
Last updated: October 18, 2012
Last verified: October 2012
History of Changes
  Purpose

This is a multi center, open label, parallel group, single administration, phase I trial, in subjects with mild, moderate or severe renal impairment and a control group with normal renal function.


Condition Intervention Phase
Renal Impairment
 Drug: NOX-E36
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Parallel Group, Multi-center Single Dose Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

Further study details as provided by Noxxon Pharma AG:

Primary Outcome Measures:
  • Pharmacokinetics [ Designated as safety issue: No ]

Enrollment: 32
Study Start Date: June 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NOX-E36
All subjects included in this study will receive the same dose of NOX E36.
 Drug: NOX-E36
All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity

Detailed Description:

Current diabetes therapy does not stop progression of the disease and the development of diabetes mellitus (DM)-associated complications. A major concern in DM-patients is renal impairment due to nephropathy leading to a reduced glomerular filtration rate (GFR). It has been established that chronic (sub)clinical inflammation is crucial for the onset and progression of DM.

CCL2, also known as Monocyte chemoattractant protein 1 (MCP 1) is a chemokine from the cysteine-cysteine family, secreted by leukocytes or tissue cells. CCL2 promotes monocyte emigration from the bone marrow, activates monocytes and macrophages and directs their migration to sites of inflammation. Recent animal studies and clinical trials indicate a critical involvement of CCL2 in DM and diabetic nephropathy, suggesting that CCL2 may be a potential target for therapeutic intervention in DM. Finally, protein overload and oxidative challenge of the diseased kidney was suggested to stimulate CCL2 expression in renal tubuli, thereby accelerating the progression of diabetic nephropathy.

As NOX E36 is designed to specifically target human MCP-1/CCL2. This study is performed to evaluate the role of renal impairment for adequate dosing recommendations in the planned target population.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male and female subjects (age 18-75 years, both inclusive)
  2. Male subjects who agree to sexual abstinence and/or use a highly effective method of birth control. Female partners of male subjects must be of non-child bearing potential or must practice an adequate non-hormonal contraceptive method to prevent pregnancies.
  3. Subjects will be categorized as follows based on creatinine clearance(mL/min/1.73m2): Normal renal function: CrCl > 80; mild renal impairment: 50 ≤ CrCl ≤ 80; moderate renal impairment: 30 ≤ CrCl ≤ 50; severe renal impairment: CrCl < 30
  4. Body Mass Index (BMI) between 22 and 40 kg/m², both inclusive.

Exclusion Criteria:

  1. Women of childbearing potential
  2. Patients who have received kidney transplantation.
  3. Patients receiving hemodialysis to control their disease.
  4. Any clinically significant abnormality other than related to the renal impairment following the investigator's review of the physical examination, ECG and clinical laboratory tests at screening.
  5. Not able to communicate meaningfully with the investigator and staff.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01372124

Locations
Hungary
DRC
Balatonfüred, Hungary, 8230
Moldova, Republic of
Innophar Mo S.R.L.
Chisinau, Moldova, Republic of
Sponsors and Collaborators
Noxxon Pharma AG
Investigators
Principal Investigator: Boris Sazu, MD INNOPHAR MO s.R.L.
Principal Investigator: Éva Péterfai DRC
  More Information

No publications provided

Responsible Party: Noxxon Pharma AG
ClinicalTrials.gov Identifier: NCT01372124     History of Changes
Other Study ID Numbers: SNOXE36C201
Study First Received: June 8, 2011
Last Updated: October 18, 2012
Health Authority: Hungary: National Institute of Pharmacy
Moldavia: Ministry of Health

Keywords provided by Noxxon Pharma AG:
Renal impairment
NOX-E36

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 23, 2013